* 2H8H - SH3, SH2 and kinase domains; apo; inactive conformation
* 1FMK - SH3, SH2 and kinase domains; apo; resid\_shift of -3; highlighted locations of phospho sites 530 and 419 (magenta), and gatekeeper site (blue); inactive conformation
* 1Y57 - SH3, SH2 and kinase domains; apo; (semi-)active extended conformation; Y530 not phosphorylated; ATP-competitive inhibitor

* 2SRC - Human Src residues 86-836, containing SH2, SH3, Kinase domain, and C-terminal tail; AMP-PNP
* 2OIQ - Chicken Src kinase domain; imatinib
* 4MXO-  Human Src kinase domain; Bosutinib
* 4MXX - Human Src kinase domain A403T; Bosutinib
* 4MXY - Human Src kinase domain M314L T338M; Bosutinib (Mention of this structure is skipped in the paper...)
* 4MXZ - Human Src kinase domain M314L T338M; Bosutinib
* 3G6H - Chicken Src kinase domain T338I; 'Src Thr338Ile inhibited in the DFG-Asp-Out conformation'; DSA compound
* 3G6G - Chicken Src kinase domain; DSA compound
* 3OEZ - Chicken Src kinase domain L317I; imatinib
* 3OF0 - Chicken Src kinase domain L317I; apo
* 3QLF - Chicken Src kinase domain L317I; pyrazolopyrimidine 5
* 3QLG - Chicken Src kinase domain L317I; dasatinib